As a result of a wide-ranging probe into generic drug price fixing, Heritage Pharmaceuticals admitted to conspiring to set prices for a diabetes medicine and will pay more than $7 million to settle civil and criminal charges.

The drug maker worked with several other companies and individuals between April 2014 and December 2015 to fix prices, rig bids, and allocate customers for the glyburide treatment, according to court documents. More than a half dozen other generic drug makers — including Aurobindo and Teva Pharmaceutical (TEVA) — sell a version of glyburide.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy